Yuying Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuying Zhao has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- Chuanzhu Yan
Department of Neurology, Shandong Key Laboratory of Mitochondrial Medicine and Rare Diseases, Research Institute of Neuromuscular and Neurodegenerative Diseases Qilu Hospital of Shandong University Jinan China
18 shared publications Wei Li
Department of Neurology, Research Institute of Neuromuscular and Neurodegenerative Diseases, Shandong Key Laboratory of Mitochondrial Medicine and Rare Diseases, Qilu Hospital of Shandong University, Jinan, China
9 shared publicationsChuanzhu Yan
Department of Neurology, Shandong Key Laboratory of Mitochondrial Medicine and Rare Diseases, Research Institute of Neuromuscular and Neurodegenerative Diseases, Qilu Hospital of Shandong University, Jinan, China
4 shared publicationsFuchen Liu
Research Institute of Neuromuscular and Neurodegenerative Disease, Department of Neurology, Cheeloo College of Medicine, Qilu Hospital, Shandong University, Jinan, China
4 shared publicationsPengfei Lin
Department of Neurology, Research Institute of Neuromuscular and Neurodegenerative Diseases Qilu Hospital of Shandong University, Shandong Key Laboratory of Mitochondrial Medicine and Rare Diseases Jinan China
4 shared publicationsDa-Nian Li
3 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Wiley in JIMD Reports
- Vol. 67 (6)
High‐Risk Screening for Late‐Onset Pompe Disease in Northern China: Prevalence, Genotypic Spectrum, and Diagnostic Challenges
Late‐onset Pompe disease (LOPD), also known as late‐onset glycogen storage disease Type II, is caused by a genetic deficiency of the lysosomal enzyme acid α‐glucosidase (GAA). LOPD typically results in progressive weakness of the limb‐girdle and respiratory muscles and is often accompanied by the involvement of other systems, such as skeleton, smooth muscle, and the cerebrovascular system. The incidence of LOPD in China remains unknown, underscoring the need for large‐scale epidemiological studies to better characterize the clinical spectrum. This prospective, multicenter, observational cohort study was conducted across 39 neurology centers in 12 northern Chinese provinces. A novel pragmatic approach was utilized, which included the development and application of a standardized high‐risk profile for LOPD suspicion, derived from collective diagnostic and therapeutic experience throughout the region. Individuals meeting 2 or more criteria in this predefined high‐risk profile were enrolled. Subsequent screening involved initial analysis of GAA enzyme activity using dried blood spot (DBS) testing and patients with deficient enzyme activity underwent confirmatory genetic testing to establish a definitive LOPD diagnosis. Between January 2022 and December 2024, 1878 high‐risk patients were enrolled. Screening identified 46 patients (2.45%) diagnosed with LOPD based on DBS analysis and subsequent genetic confirmation. This study demonstrates a significant prevalence of LOPD among a clinically high‐risk population in Northern China. These findings underscore the critical importance of targeted screening programs for early identification. Early diagnosis enables timely initiation of enzyme replacement therapy (ERT), which can significantly mitigate the disease course, improve quality of life, and reduce long‐term healthcare burden.
- 13 November 2026
- Published by Wiley in JIMD Reports
- Vol. 67 (6)
Open AccessHigh‐Risk Screening for Late‐Onset Pompe Disease in Northern China: Prevalence, Genotypic Spectrum, and Diagnostic Challenges
Late‐onset Pompe disease (LOPD), also known as late‐onset glycogen storage disease Type II, is caused by a genetic deficiency of the lysosomal enzyme acid α‐glucosidase (GAA). LOPD typically results in progressive weakness of the limb‐girdle and respiratory muscles and is often accompanied by the involvement of other systems, such as skeleton, smooth muscle, and the cerebrovascular system. The incidence of LOPD in China remains unknown, underscoring the need for large‐scale epidemiological studies to better characterize the clinical spectrum. This prospective, multicenter, observational cohort study was conducted across 39 neurology centers in 12 northern Chinese provinces. A novel pragmatic approach was utilized, which included the development and application of a standardized high‐risk profile for LOPD suspicion, derived from collective diagnostic and therapeutic experience throughout the region. Individuals meeting 2 or more criteria in this predefined high‐risk profile were enrolled. Subsequent screening involved initial analysis of GAA enzyme activity using dried blood spot (DBS) testing and patients with deficient enzyme activity underwent confirmatory genetic testing to establish a definitive LOPD diagnosis. Between January 2022 and December 2024, 1878 high‐risk patients were enrolled. Screening identified 46 patients (2.45%) diagnosed with LOPD based on DBS analysis and subsequent genetic confirmation. This study demonstrates a significant prevalence of LOPD among a clinically high‐risk population in Northern China. These findings underscore the critical importance of targeted screening programs for early identification. Early diagnosis enables timely initiation of enzyme replacement therapy (ERT), which can significantly mitigate the disease course, improve quality of life, and reduce long‐term healthcare burden.
- Open Access
- 25 September 2026
- Published by Springer Nature in BMC Neurology
Effectiveness and safety of risdiplam in Chinese adolescents and adults with spinal muscular atrophy: a prospective real-world study
Background: Evidence for the efficacy of risdiplam in adolescents and adults with 5q spinal muscular atrophy (SMA) has been demonstrated in clinical trials, but its sustained effectiveness and safety in real-world settings, particularly in Chinese adults, are still limited. We evaluated the effectiveness and safety of risdiplam in this population in a real-world setting. Methods: This prospective observational study included adolescent and adult patients with genetically confirmed 5q SMA under standard clinical care (January 2023 to December 2024). Patients received risdiplam monotherapy with a maintenance dose of 5 mg daily. Primary outcomes were changes in Hammersmith Functional Motor Scale Expanded (HFMSE), Revised Upper Limb Module (RULM) scores, and 6-min walk test (6MWT). Results: Fifteen patients (8 male, 7 female) were included, with a median effectiveness assessment time of 1.38 years (IQR, 1.30–1.56). The median RULM score significantly improved from 18.00 (IQR, 10.00-25.50) at baseline to 21.00 (IQR, 12.00-26.50) at final follow-up ( P = 0.043). The median HFMSE score showed a non-significant increase [9.00 (IQR, 1.50–14.50) vs. 9.00 (IQR, 3.50–15.50), P = 0.159]. The 6-minute walk test remained stable, with improvement observed in two patients. The median ALSFRS-R scores remained stable [33.00 (IQR, 26.00–35.00) vs. 32.00 (IQR, 26.50–36.00), P = 0.936]. No adverse events were reported, indicating good tolerability. Conclusions: In this exploratory real-world study, our findings provide evidence supporting the potential effectiveness and safety of risdiplam in managing SMA in adolescent and adult patients. Longer-term and larger-scale studies remain warranted to further characterize its clinical durability.
- 25 September 2026
- Published by Springer Nature in BMC Neurology
Open AccessEffectiveness and safety of risdiplam in Chinese adolescents and adults with spinal muscular atrophy: a prospective real-world study
Background: Evidence for the efficacy of risdiplam in adolescents and adults with 5q spinal muscular atrophy (SMA) has been demonstrated in clinical trials, but its sustained effectiveness and safety in real-world settings, particularly in Chinese adults, are still limited. We evaluated the effectiveness and safety of risdiplam in this population in a real-world setting. Methods: This prospective observational study included adolescent and adult patients with genetically confirmed 5q SMA under standard clinical care (January 2023 to December 2024). Patients received risdiplam monotherapy with a maintenance dose of 5 mg daily. Primary outcomes were changes in Hammersmith Functional Motor Scale Expanded (HFMSE), Revised Upper Limb Module (RULM) scores, and 6-min walk test (6MWT). Results: Fifteen patients (8 male, 7 female) were included, with a median effectiveness assessment time of 1.38 years (IQR, 1.30–1.56). The median RULM score significantly improved from 18.00 (IQR, 10.00-25.50) at baseline to 21.00 (IQR, 12.00-26.50) at final follow-up ( P = 0.043). The median HFMSE score showed a non-significant increase [9.00 (IQR, 1.50–14.50) vs. 9.00 (IQR, 3.50–15.50), P = 0.159]. The 6-minute walk test remained stable, with improvement observed in two patients. The median ALSFRS-R scores remained stable [33.00 (IQR, 26.00–35.00) vs. 32.00 (IQR, 26.50–36.00), P = 0.936]. No adverse events were reported, indicating good tolerability. Conclusions: In this exploratory real-world study, our findings provide evidence supporting the potential effectiveness and safety of risdiplam in managing SMA in adolescent and adult patients. Longer-term and larger-scale studies remain warranted to further characterize its clinical durability.
- Open Access
- 31 August 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN): integrating epidemiological insights with diagnostic and therapeutic progress
Background: Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a progressive, fatal multisystem disorder characterized by significant genotypic and geographic heterogeneity. Despite recent therapeutic breakthroughs, overlapping clinical features frequently lead to misdiagnosis and delayed intervention. Methods: A comprehensive narrative review of the literature was conducted to synthesize recent advancements in the epidemiology, diagnostic workflows, and therapeutic landscape of ATTRv-PN, with an emphasis on clinical translation and multidisciplinary management. Results: The epidemiological profile of ATTRv-PN highlights region-specific variant distributions (e.g., p.Val50Met, p.Ala117Ser). The diagnostic paradigm has shifted towards prioritizing early genetic testing and minimally invasive biopsies, complemented by emerging serum biomarkers like neurofilament light chain (NfL) and advanced neuroimaging. Therapeutically, the landscape has been transformed by disease-modifying therapies (DMTs). Gene-silencing agents (siRNAs and ASOs) and TTR stabilizers have demonstrated robust efficacy in halting neuropathy progression. Furthermore, novel modalities, including amyloid-depleting monoclonal antibodies and in vivo CRISPR/Cas9 gene-editing therapies, show unprecedented promise in ongoing clinical trials. Conclusions: ATTRv-PN has entered an era of precision medicine. Overcoming diagnostic delays through “red-flag” recognition and routine genetic screening is imperative. Early, stage-adapted initiation of DMTs within a multidisciplinary care framework is crucial for optimizing long-term patient outcomes.
- 31 August 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
Open AccessHereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN): integrating epidemiological insights with diagnostic and therapeutic progress
Background: Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a progressive, fatal multisystem disorder characterized by significant genotypic and geographic heterogeneity. Despite recent therapeutic breakthroughs, overlapping clinical features frequently lead to misdiagnosis and delayed intervention. Methods: A comprehensive narrative review of the literature was conducted to synthesize recent advancements in the epidemiology, diagnostic workflows, and therapeutic landscape of ATTRv-PN, with an emphasis on clinical translation and multidisciplinary management. Results: The epidemiological profile of ATTRv-PN highlights region-specific variant distributions (e.g., p.Val50Met, p.Ala117Ser). The diagnostic paradigm has shifted towards prioritizing early genetic testing and minimally invasive biopsies, complemented by emerging serum biomarkers like neurofilament light chain (NfL) and advanced neuroimaging. Therapeutically, the landscape has been transformed by disease-modifying therapies (DMTs). Gene-silencing agents (siRNAs and ASOs) and TTR stabilizers have demonstrated robust efficacy in halting neuropathy progression. Furthermore, novel modalities, including amyloid-depleting monoclonal antibodies and in vivo CRISPR/Cas9 gene-editing therapies, show unprecedented promise in ongoing clinical trials. Conclusions: ATTRv-PN has entered an era of precision medicine. Overcoming diagnostic delays through “red-flag” recognition and routine genetic screening is imperative. Early, stage-adapted initiation of DMTs within a multidisciplinary care framework is crucial for optimizing long-term patient outcomes.
- Open Access
- 3 August 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (8) , e71068
CLRN1 Variants in Müller Cells Cause Mitochondrial Dysfunction in USH3A Retinal Organoids
Background: Usher syndrome 3A (USH3A), caused by mutations in the CLRN1 gene, leads to retinitis pigmentosa and sensorineural hearing loss. While CLRN1 's role in inner ear pathology is established, its contribution to retinal degeneration remains poorly understood. Methods: Retinal organoids derived from a USH3A patient were analyzed using single‐cell RNA sequencing and multi‐electrode array recording. CLRN1 expression was mapped in human fetal retina and organoids. We assessed the structural, transcriptional, and functional impact of CLRN1 variants on Müller cells and photoreceptors, and evaluated idebenone as a potential targeted therapy. Results: CLRN1 was specifically expressed in Müller cells. CLRN1 variants induced severe retinal degeneration, characterized by outer nuclear layer thinning, impaired photoreceptor gene expression, activated apoptosis, and diminished electrophysiological function. Mechanistically, these variants caused mitochondrial dysfunction in Müller cells, which triggered secondary mitochondrial impairment, oxidative stress, and apoptosis in photoreceptors. Idebenone treatment partially rescued these deficits. Conclusions: CLRN1 ‐related mitochondrial impairment in Müller cells contributes to the pathogenesis of retinitis pigmentosa in USH3A. These findings identify Müller cell mitochondrial dysfunction as a key disease mechanism and highlight potential therapeutic targets.
- 3 August 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (8) , e71068
Open AccessCLRN1 Variants in Müller Cells Cause Mitochondrial Dysfunction in USH3A Retinal Organoids
Background: Usher syndrome 3A (USH3A), caused by mutations in the CLRN1 gene, leads to retinitis pigmentosa and sensorineural hearing loss. While CLRN1 's role in inner ear pathology is established, its contribution to retinal degeneration remains poorly understood. Methods: Retinal organoids derived from a USH3A patient were analyzed using single‐cell RNA sequencing and multi‐electrode array recording. CLRN1 expression was mapped in human fetal retina and organoids. We assessed the structural, transcriptional, and functional impact of CLRN1 variants on Müller cells and photoreceptors, and evaluated idebenone as a potential targeted therapy. Results: CLRN1 was specifically expressed in Müller cells. CLRN1 variants induced severe retinal degeneration, characterized by outer nuclear layer thinning, impaired photoreceptor gene expression, activated apoptosis, and diminished electrophysiological function. Mechanistically, these variants caused mitochondrial dysfunction in Müller cells, which triggered secondary mitochondrial impairment, oxidative stress, and apoptosis in photoreceptors. Idebenone treatment partially rescued these deficits. Conclusions: CLRN1 ‐related mitochondrial impairment in Müller cells contributes to the pathogenesis of retinitis pigmentosa in USH3A. These findings identify Müller cell mitochondrial dysfunction as a key disease mechanism and highlight potential therapeutic targets.
- Open Access
- 5 May 2026
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14
Adult-onset Sandhoff disease presenting with a motor neuron disease phenotype: clinical and mechanistic insights from patient-derived models
Sandhoff disease (SD) is a subtype of GM2 gangliosidosis caused by pathogenic variants in Hexosaminidase B (HEXB). It most frequently presents in infancy or early childhood, whereas adult-onset disease is rare and remains incompletely characterized. Here, we describe an adult-onset case of SD presenting as motor neuron disease and provide clinical and mechanistic insights using patient-derived models. The patient was a 34-year-old man with compound heterozygous HEXB variants (c.1598G > A, p.Arg533His and c.1645G > A, p.Gly549Arg) who developed progressive lower limb weakness. Muscle biopsy demonstrated neurogenic changes consistent with denervation, and sural nerve biopsy revealed mild peripheral neuropathy. Nerve conduction studies and electromyography showed widespread neurogenic changes with mildly reduced sensory nerve action potential amplitudes, and leukocyte β-hexosaminidase activity was decreased. To investigate disease mechanisms, we generated induced pluripotent stem cells (iPSCs) from the patient and an isogenic CRISPR-Cas9-corrected control (ISO), and differentiated both lines into motor neurons (MNs). In the SD patient (SDHF)-derived MNs, we observed lysosomal expansion, increased apoptosis, reduced neuronal network excitability, and dysregulated lipidomic profiles. These phenotypes were attenuated in MNs derived from the ISO line, with multiple measures shifting toward those of control (CTL) MNs. Collectively, our findings expand the clinical spectrum of adult-onset SD and support an association between HEXB deficiency and the vulnerability of MNs, while underscoring the value of patient-derived iPSC models for mechanistic studies of lateonset SD.
- 5 May 2026
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14
Open AccessAdult-onset Sandhoff disease presenting with a motor neuron disease phenotype: clinical and mechanistic insights from patient-derived models
Sandhoff disease (SD) is a subtype of GM2 gangliosidosis caused by pathogenic variants in Hexosaminidase B (HEXB). It most frequently presents in infancy or early childhood, whereas adult-onset disease is rare and remains incompletely characterized. Here, we describe an adult-onset case of SD presenting as motor neuron disease and provide clinical and mechanistic insights using patient-derived models. The patient was a 34-year-old man with compound heterozygous HEXB variants (c.1598G > A, p.Arg533His and c.1645G > A, p.Gly549Arg) who developed progressive lower limb weakness. Muscle biopsy demonstrated neurogenic changes consistent with denervation, and sural nerve biopsy revealed mild peripheral neuropathy. Nerve conduction studies and electromyography showed widespread neurogenic changes with mildly reduced sensory nerve action potential amplitudes, and leukocyte β-hexosaminidase activity was decreased. To investigate disease mechanisms, we generated induced pluripotent stem cells (iPSCs) from the patient and an isogenic CRISPR-Cas9-corrected control (ISO), and differentiated both lines into motor neurons (MNs). In the SD patient (SDHF)-derived MNs, we observed lysosomal expansion, increased apoptosis, reduced neuronal network excitability, and dysregulated lipidomic profiles. These phenotypes were attenuated in MNs derived from the ISO line, with multiple measures shifting toward those of control (CTL) MNs. Collectively, our findings expand the clinical spectrum of adult-onset SD and support an association between HEXB deficiency and the vulnerability of MNs, while underscoring the value of patient-derived iPSC models for mechanistic studies of lateonset SD.
- Open Access
- 28 April 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1797345
Clinical, pathological and genetic features as well as follow-up of 68 patients with late-onset Pompe disease: a single-center retrospective study
Introduction: Pompe disease is a muscular lysosomal storage disorder characterized by autosomal recessive inheritance and caused by deficiency of the acid alpha-glucosidase (GAA) enzyme. Late-onset Pompe disease (LOPD) exhibits heterogeneous clinical presentations, which are influenced by the type of GAA mutation and residual enzyme activity. Methods: In this study, we conducted a retrospective analysis of 68 Chinese LOPD patients over a 17-year period at a single center to delineate the real-world disease status and survival outcomes. Results: Among the 47 patients who received enzyme replacement therapy (ERT), the mortality rate was 6.4%, compared to 57.1% in the 21 patients who did not receive ERT. Muscle pathology analysis revealed that glycogenin accumulation appears earlier than autophagy marker, but this finding is exploratory and requires validation in larger studies. The severity of muscle pathology correlated with lower body mass index (BMI), shorter 6-min walk test (6MWT) and spinal curvature abnormalities. The most frequent GAA gene mutation identified was c.2238G > C (p.W746C), present in 43.3% of patients. In an exploratory subgroup analysis ( n = 10), patients who initiated ERT shortly after diagnosis exhibited greater improvements in muscle strength and 6MWT results compared to those who started treatment later; however, the small sample size precludes definitive conclusions. Conclusion: In summary, our exploratory findings hypothesize that glycogenin may be an early pathological marker, but this requires prospective validation. ERT was associated with higher survival probability in this cohort, although survival bias limits causal inference. Earlier ERT initiation showed an association with better functional outcomes in a small subgroup. Lower BMI, shorter 6MWT, and spinal curvature abnormalities correlated with more severe muscle pathology in univariate analyses. All findings should be interpreted as hypothesis-generating due to study limitations.
- 28 April 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1797345
Open AccessClinical, pathological and genetic features as well as follow-up of 68 patients with late-onset Pompe disease: a single-center retrospective study
Introduction: Pompe disease is a muscular lysosomal storage disorder characterized by autosomal recessive inheritance and caused by deficiency of the acid alpha-glucosidase (GAA) enzyme. Late-onset Pompe disease (LOPD) exhibits heterogeneous clinical presentations, which are influenced by the type of GAA mutation and residual enzyme activity. Methods: In this study, we conducted a retrospective analysis of 68 Chinese LOPD patients over a 17-year period at a single center to delineate the real-world disease status and survival outcomes. Results: Among the 47 patients who received enzyme replacement therapy (ERT), the mortality rate was 6.4%, compared to 57.1% in the 21 patients who did not receive ERT. Muscle pathology analysis revealed that glycogenin accumulation appears earlier than autophagy marker, but this finding is exploratory and requires validation in larger studies. The severity of muscle pathology correlated with lower body mass index (BMI), shorter 6-min walk test (6MWT) and spinal curvature abnormalities. The most frequent GAA gene mutation identified was c.2238G > C (p.W746C), present in 43.3% of patients. In an exploratory subgroup analysis ( n = 10), patients who initiated ERT shortly after diagnosis exhibited greater improvements in muscle strength and 6MWT results compared to those who started treatment later; however, the small sample size precludes definitive conclusions. Conclusion: In summary, our exploratory findings hypothesize that glycogenin may be an early pathological marker, but this requires prospective validation. ERT was associated with higher survival probability in this cohort, although survival bias limits causal inference. Earlier ERT initiation showed an association with better functional outcomes in a small subgroup. Lower BMI, shorter 6MWT, and spinal curvature abnormalities correlated with more severe muscle pathology in univariate analyses. All findings should be interpreted as hypothesis-generating due to study limitations.
- Open Access
- 14 March 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (3) , e70540
Clinical and Pathological Features of Vasculitic Neuropathy: A Single‐Center Study in China
Background: Vasculitic neuropathy (VN) is a disease in which vessel inflammation happens and injures peripheral nerves. Despite increasing awareness, features of VN in mainland China are still understudied. Objective: To characterize the clinical, pathological features and outcomes of VN in mainland China, and evaluate clinicopathological correlations: Methods: We retrospectively reviewed records of VN patients diagnosed pathologically between June 1999 and December 2024, including demographic data, clinical manifestations, biopsy features, and outcomes. Results: 112 patients were totally included. All presented with axonal sensorimotor neuropathy, most commonly involving the tibial (90.63%) and peroneal (87.50%) nerves. Systemic VN (SVN) showed more frequent transmural inflammatory cell infiltration (ICI) than non‐systemic VN (NSVN) ( p = 0.046). Eosinophilic granulomatosis with polyangiitis (EGPA) was more common in VN without ICI than VN with ICI ( p = 0.008). In SVN, the ICI‐positive exhibited more severe distal upper limb weakness ( p = 0.042) and higher thrombosis rates ( p = 0.001) than ICI‐negative. Of the 63 patients followed, 62 received glucocorticoids with or without immunosuppressants. Thirteen died from multi‐organ complications (12 SVN and 1 NSVN), while others achieved remission. The 5‐year all‐survival rate was 80.23% (95% CI 66.83%– 88.66%). Conclusions: This first large cohort of VN in mainland China delineates its clinical–pathological features. EGPA showed a lower diagnostic yield on biopsy, suggesting diverse mechanisms of vascular injury. Nerve biopsy remains the diagnostic gold standard. The overall prognosis of VN is relatively favorable, emphasizing the need for early recognition and treatment.
- 14 March 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (3) , e70540
Open AccessClinical and Pathological Features of Vasculitic Neuropathy: A Single‐Center Study in China
Background: Vasculitic neuropathy (VN) is a disease in which vessel inflammation happens and injures peripheral nerves. Despite increasing awareness, features of VN in mainland China are still understudied. Objective: To characterize the clinical, pathological features and outcomes of VN in mainland China, and evaluate clinicopathological correlations: Methods: We retrospectively reviewed records of VN patients diagnosed pathologically between June 1999 and December 2024, including demographic data, clinical manifestations, biopsy features, and outcomes. Results: 112 patients were totally included. All presented with axonal sensorimotor neuropathy, most commonly involving the tibial (90.63%) and peroneal (87.50%) nerves. Systemic VN (SVN) showed more frequent transmural inflammatory cell infiltration (ICI) than non‐systemic VN (NSVN) ( p = 0.046). Eosinophilic granulomatosis with polyangiitis (EGPA) was more common in VN without ICI than VN with ICI ( p = 0.008). In SVN, the ICI‐positive exhibited more severe distal upper limb weakness ( p = 0.042) and higher thrombosis rates ( p = 0.001) than ICI‐negative. Of the 63 patients followed, 62 received glucocorticoids with or without immunosuppressants. Thirteen died from multi‐organ complications (12 SVN and 1 NSVN), while others achieved remission. The 5‐year all‐survival rate was 80.23% (95% CI 66.83%– 88.66%). Conclusions: This first large cohort of VN in mainland China delineates its clinical–pathological features. EGPA showed a lower diagnostic yield on biopsy, suggesting diverse mechanisms of vascular injury. Nerve biopsy remains the diagnostic gold standard. The overall prognosis of VN is relatively favorable, emphasizing the need for early recognition and treatment.
- Open Access
- 13 March 2026
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 148 (2) , 109874
Alglucosidase alfa demonstrates effectiveness and safety in Chinese patients with late-onset Pompe disease: A multi-center prospective study
- 13 March 2026
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 148 (2) , 109874
Open AccessAlglucosidase alfa demonstrates effectiveness and safety in Chinese patients with late-onset Pompe disease: A multi-center prospective study
- 1 January 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (1) , e8-e9
Cerebral Artery Ectasia in Brucella
- 1 January 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (1) , e8-e9
Cerebral Artery Ectasia in Brucella
- Open Access
- 30 November 2025
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Intractable & Rare Diseases Research
- Vol. 14 (4) , 277-287
Clinical and genetic characteristics of late-onset cobalamin C deficiency: A multicenter study in northern China
Late-onset cobalamin C (cblC) deficiency, an inherited metabolic disorder, is often misdiagnosed due to its heterogeneous clinical presentation. This study aims to characterize the clinical and genetic spectrum of late-onset cblC deficiency in a large northern Chinese cohort and proposes a novel clinical classification based on initial symptoms. A retrospective, multicenter study of 156 patients diagnosed between October 2012 and December 2023 was conducted. Clinical, biochemical, neuroimaging, and genetic data were analyzed. Patients were classified into six subtypes based on predominant initial symptoms, and genotype-phenotype correlations were explored. The cohort (95 males, 61 females) had a median onset age of 16 years (range: 2–65). Common symptoms included spastic paralysis (41.0%), mental and behavioral abnormalities (36.5%), and renal damage (28.8%). Genetic analysis identified 52 MMACHC variants, with c.482G>A (34.3%) and c.609G>A (17.6%) being most frequent. Elevated total homocysteine (tHcy) levels correlated with mental and behavioral abnormalities, renal damage, and anemia (p < 0.05). The proposed clinical classification identified six subtypes, with encephalopathy-dominant and encephalomyelopathy-dominant types being most prevalent. This study highlights the clinical heterogeneity of late-onset cblC deficiency and introduces a novel symptom-based classification system to aid diagnosis and management. Elevated tHcy levels and specific MMACHC variants are key biomarkers for disease severity. These findings underscore the importance of early intervention to improve outcomes.
- 30 November 2025
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Intractable & Rare Diseases Research
- Vol. 14 (4) , 277-287
Open AccessClinical and genetic characteristics of late-onset cobalamin C deficiency: A multicenter study in northern China
Late-onset cobalamin C (cblC) deficiency, an inherited metabolic disorder, is often misdiagnosed due to its heterogeneous clinical presentation. This study aims to characterize the clinical and genetic spectrum of late-onset cblC deficiency in a large northern Chinese cohort and proposes a novel clinical classification based on initial symptoms. A retrospective, multicenter study of 156 patients diagnosed between October 2012 and December 2023 was conducted. Clinical, biochemical, neuroimaging, and genetic data were analyzed. Patients were classified into six subtypes based on predominant initial symptoms, and genotype-phenotype correlations were explored. The cohort (95 males, 61 females) had a median onset age of 16 years (range: 2–65). Common symptoms included spastic paralysis (41.0%), mental and behavioral abnormalities (36.5%), and renal damage (28.8%). Genetic analysis identified 52 MMACHC variants, with c.482G>A (34.3%) and c.609G>A (17.6%) being most frequent. Elevated total homocysteine (tHcy) levels correlated with mental and behavioral abnormalities, renal damage, and anemia (p < 0.05). The proposed clinical classification identified six subtypes, with encephalopathy-dominant and encephalomyelopathy-dominant types being most prevalent. This study highlights the clinical heterogeneity of late-onset cblC deficiency and introduces a novel symptom-based classification system to aid diagnosis and management. Elevated tHcy levels and specific MMACHC variants are key biomarkers for disease severity. These findings underscore the importance of early intervention to improve outcomes.